Clinical Trials Logo

Biliary Tract Cancer clinical trials

View clinical trials related to Biliary Tract Cancer.

Filter by:

NCT ID: NCT01294085 Completed - Clinical trials for Biliary Tract Cancer

Case Series Study of Biliary Tract Cancer Patients in Japan

Start date: November 2010
Phase: N/A
Study type: Observational

To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.

NCT ID: NCT01291615 Completed - Clinical trials for Biliary Tract Cancer

Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Start date: December 2010
Phase: Phase 1
Study type: Interventional

To decide maximum tolerated dose and/or recommended dose of Gemcitabine or S-1 adjuvant therapy after hemihepatectomy

NCT ID: NCT01284413 Completed - Clinical trials for Biliary Tract Cancer

Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety of GCS therapy for phase I and efficacy of GCS therapy for phase II.

NCT ID: NCT00832689 Completed - Clinical trials for Biliary Tract Cancer

Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.

NCT ID: NCT00753675 Completed - Clinical trials for Biliary Tract Cancer

Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

VANGOGH
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic) biliary tract cancer.

NCT ID: NCT00423254 Completed - Gastric Cancer Clinical Trials

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.

NCT ID: NCT00380588 Completed - Clinical trials for Biliary Tract Cancer

Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer

Start date: September 2006
Phase: Phase 2
Study type: Interventional

To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer

NCT ID: NCT00361231 Completed - Clinical trials for Biliary Tract Cancer

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purposes of this study are to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good and bad) this combination has on patients with cancer of bile duct or gallbladder. Bevacizumab has been shown to slow or stop cell growth in tumors by decreasing the blood supply to the tumors.

NCT ID: NCT00339560 Completed - Clinical trials for Biliary Tract Cancer

A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China

Start date: May 16, 1997
Phase:
Study type: Observational

The key aims of this study include estimation of possible risk associated with a history of gallstones, bacterial infection for the biliary tract, other medical history, diet, use of tobacco and alcohol, obesity, reproductive factors, and family history of cancer. Information will be used to examine risk patterns a) seperately by anatomic subsite; b) among patients with gallbladder cancer vs. controls undergoing cholecystectomy for gallstones; c) among the patients with bile duct cancer vs. Hospital controls without cancer who undergo surgery for removal of bile duct stones. We will also attempt to ascertain reasons for cancer who undergo surgery for removal of bile duct stones. We will also attempt to ascertain reasons for the rising incidence of biliary tract cancers in Shanghai. Serum collected from all subjects will be analyzed for estrogens and other hormones, vitamins C and E, cholesterol, and bacterial antibodies (including salmonella typhi, paratyphi, and escherischia coli). Bile fluid will be cultured for aerobic bacteria, and gallstones analyzed for color, cholesterol, and evidence of bacteria infection. A major challenge in biliary tract cancer research is to determine how cancer risk factors differ from those for gallstones or biliary duct stone disease, since many people have gallstones (or biliary duct stones) but few develop cancer....

NCT ID: NCT00142480 Completed - Clinical trials for Biliary Tract Cancer

Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary tract and gallbladder cancer.